查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1613062

全球胶原蛋白血液学市场（依产品、适应症、最终用途）：未来预测（2025-2030）

Collagen Vascular Diseases Market by Product (Diagnosis, Treatments), Indication (Ankylosing Spondylitis, Dermatomyositis, Polyarteritis Nodosa), End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年胶原蛋白血液学市场价值为298.3亿美元，预计到2024年将达到322.1亿美元，复合年增长率为8.70%，到2030年将达到535.1亿美元，预计将会增长。

胶原蛋白血液疾病 (CVD) 是一组自体免疫疾病，人体的免疫系统错误地攻击胶原蛋白（结缔组织的重要组成部分）。 CVD药物的需求和应用在于解决狼疮、硬皮症和类风湿性关节炎等患者遭受发炎、疼痛和组织损伤的疾病。这些治疗药物不仅可以改善患者的生活质量，而且对于降低与慢性病长期管理相关的医疗成本也至关重要。最终用途包括提供处方药或先进生技药品治疗的医院、诊所和专科医疗中心。推动市场成长的主要因素是治疗方法的技术进步、自体免疫疾病盛行率的增加以及对早期诊断和早期疗育的认识的提高。个人化医疗和标靶治疗的发展存在重大机会，有望提高疗效并减少副作用。公司应专注于利用人工智慧主导的分析进行患者资料分析，并整合远端医疗服务以更好地推广和病患监测。

主要市场统计
基准年[2023] 298.3亿美元
预计年份 [2024] 322.1亿美元
预测年份 [2030] 535.1亿美元
复合年增长率（%） 8.70%

然而，市场面临重大挑战，包括高昂的治疗成本、严格的监管核准以及与长期使用免疫抑制剂相关的潜在副作用。此外，自体免疫疾病机制的复杂性往往使药物开发和研究变得复杂。解决这些方面对于市场扩张可能至关重要。生物标记识别的创新和基因研究的进步为突破提供了肥沃的土壤，特别是在个人化医疗和精准医疗方面。製药公司和研究机构之间的合作研究有可能引领新型疗法的开发，并得到政府和私人资助措施的进一步促进。心血管疾病药物市场的特点是技术创新迅速、患者经济负担和进入障碍，呈现出进步潜力和固有挑战的双重维度。

市场动态：快速发展的胶原蛋白疾病市场的关键市场洞察

供应和需求的动态相互作用正在改变胶原蛋白血液学市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 提高对胶原蛋白血液疾病的认识与了解
    • 自体自体免疫疾病的兴起
    • 改善医疗基础设施，提高医疗服务可近性
  • 市场限制因素
    • 与先进治疗和药物相关的高成本
  • 市场机会
    • 基因治疗和干细胞治疗的持续进展
    • 采用远端医疗、行动医疗应用和穿戴式装置进行病患管理
  • 市场挑战
    • 严格的政府法规和核准流程

波特五力：驾驭胶原蛋白疾病市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解胶原蛋白疾病血液疾病市场的外部影响

外部宏观环境因素在塑造胶原蛋白血液学市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解胶原蛋白血液学市场的竞争格局

对胶原血液学市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：胶原蛋白疾病血液疾病市场供应商的绩效评估

FPNV定位矩阵是评估胶原蛋白血液学市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製胶原蛋白血液学市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，胶原蛋白血液学市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估市场范围和整体影响力。

2. 市场开发：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析最近的产品发布、开拓的地区、关键产业进展以及塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1. 目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3. 塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 哪些收益来源和策略机会推动供应商的进入和退出策略？

目录

第一章简介

第二章 分析方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 提高对胶原蛋白血液疾病的认识与了解
      • 全球自体免疫疾病的发生率上升
      • 改善医疗基础设施并增加获得医疗服务的机会
    • 抑制因素
      • 与先进治疗和药物相关的高成本
    • 机会
      • 基因和干细胞治疗的持续进展
      • 部署远端医疗、行动医疗应用程式和穿戴式装置进行病患管理
    • 任务
      • 严格的政府法规和核准流程
  • 市场区隔分析
    • 产品：切片检查套件在胶原血液疾病的使用增加
    • 适应症：越来越多用于治疗皮肌炎
    • 最终用途：扩大在诊断中心和实验室的用途，以诊断各种健康状况
  • 波特五力分析
  • PESTEL分析
    • 政治因素
    • 经济因素
    • 社会因素
    • 技术因素
    • 法律因素
    • 环境因素

第六章胶原蛋白疾病血液疾病市场：副产品

  • 诊断
    • 切片检查
    • 验血
    • 心臟超音波图
    • 影像检查
    • 尿液检查
  • 治疗
    • 药物治疗
    • 物理治疗

第七章胶原蛋白疾病血液疾病市场：依适应症分类

  • 僵直性脊椎炎
  • 皮肌炎
  • 结节性多动脉炎
  • 多发性肌炎
  • 干癣性关节炎
  • 復发性多发性软骨炎
  • 类风湿性关节炎
  • 硬皮症
  • 全身性红斑性狼疮
  • 血管炎

第八章胶原病血液疾病市场：依最终用途分类

  • 诊断中心/检查室
  • 医院/诊所

第九章 北美和南美胶原病血液疾病市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区胶原病血液疾病市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲胶原病血液病市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 市场占有率分析（2023）
  • FPNV定位矩阵（2023）
  • 竞争场景分析
    • Quest Diagnostics 与 Cipher Medicine 合作，扩大类类风湿性关节炎患者获得精准医疗的机会
    • FDA核准首个托珠单抗生物相似药用于治疗类风湿性关节炎、幼年类风湿性关节炎
    • 美国风湿病学会推出新套件包来衡量类风湿性关节炎的结果
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Apollo Health and Lifestyle Limited
  • Augurex Life Sciences Corporation
  • Bayer AG
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Exagen Inc.
  • F. Hoffmann-La Roche Ltd
  • Getinge AB
  • Gilead Sciences, Inc.
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • LeMaitre Vascular, Inc.
  • Merck KGaA
  • Novartis AG
  • PerkinElmer, Inc.
  • Pfizer Inc,
  • QIAGEN GmbH
  • Siemens AG
  • Thermo Fisher Scientific, Inc.
  • Trinity Biotech PLC
Product Code: MRR-144C638C8F82

The Collagen Vascular Diseases Market was valued at USD 29.83 billion in 2023, expected to reach USD 32.21 billion in 2024, and is projected to grow at a CAGR of 8.70%, to USD 53.51 billion by 2030.

Collagen Vascular Diseases (CVDs) represent a group of autoimmune disorders where the body's immune system mistakenly attacks its collagen, an integral component of connective tissues. The necessity and application of CVD therapeutics lie in addressing diseases such as lupus, scleroderma, and rheumatoid arthritis, where patients suffer from inflammation, pain, and tissue damage. These therapies are vital not only for improving patient quality of life but also for reducing healthcare costs associated with long-term management of chronic symptoms. The end-use scope spans hospitals, clinics, and specialized care centers where treatments are administered either through prescription medication or advanced biologics. Market growth is chiefly influenced by technological advancements in treatment methodologies, increasing prevalence of autoimmune conditions, and rising awareness about early diagnosis and intervention. Key opportunities exist in the development of personalized medicine and targeted therapies, promising enhanced efficacy and reduced side effects. Companies should focus on leveraging AI-driven analytics for patient data analysis and integrating telemedicine services for better outreach and patient monitoring.

KEY MARKET STATISTICS
Base Year [2023] USD 29.83 billion
Estimated Year [2024] USD 32.21 billion
Forecast Year [2030] USD 53.51 billion
CAGR (%) 8.70%

However, the market faces significant challenges such as high treatment costs, stringent regulatory approvals, and potential side effects associated with long-term use of immunosuppressive drugs. Additionally, the complexity of autoimmune disease mechanisms often complicates drug development and research. Addressing these aspects could be critical for market expansion. Innovations in biomarker identification and advancements in genetic research offer fertile ground for breakthroughs, particularly in personalized and precision medicine. Collaborations between pharmaceutical companies and research institutions could spearhead the development of novel therapeutics, further propelled by governmental and private funding initiatives. The CVD therapeutics market is characterized by rapid technological embrace yet hurdles in patient affordability and access, indicating a dual nature of progressive potential and inherent challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Collagen Vascular Diseases Market

The Collagen Vascular Diseases Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing awareness and understanding of collagen vascular diseases
    • Rising incidence of autoimmune diseases globally
    • Improved healthcare infrastructure and increased accessibility to medical services
  • Market Restraints
    • High cost associated with advanced treatments and medications
  • Market Opportunities
    • Ongoing advancements in gene and stem cell therapies
    • Adoption of telemedicine, mobile health applications, and wearables for patient management
  • Market Challenges
    • Stringent government regulations and approval processes

Porter's Five Forces: A Strategic Tool for Navigating the Collagen Vascular Diseases Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Collagen Vascular Diseases Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Collagen Vascular Diseases Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Collagen Vascular Diseases Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Collagen Vascular Diseases Market

A detailed market share analysis in the Collagen Vascular Diseases Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Collagen Vascular Diseases Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Collagen Vascular Diseases Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Collagen Vascular Diseases Market

A strategic analysis of the Collagen Vascular Diseases Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Collagen Vascular Diseases Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Apollo Health and Lifestyle Limited, Augurex Life Sciences Corporation, Bayer AG, Beckman Coulter, Inc., Bio-Rad Laboratories Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Eli Lilly and Company, Exagen Inc., F. Hoffmann-La Roche Ltd, Getinge AB, Gilead Sciences, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, LeMaitre Vascular, Inc., Merck KGaA, Novartis AG, PerkinElmer, Inc., Pfizer Inc,, QIAGEN GmbH, Siemens AG, Thermo Fisher Scientific, Inc., and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Collagen Vascular Diseases Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Diagnosis and Treatments. The Diagnosis is further studied across Biopsy, Blood Test, Echocardiogram, Imaging Tests, and Urinalysis. The Treatments is further studied across Medications and Physical Therapy.
  • Based on Indication, market is studied across Ankylosing Spondylitis, Dermatomyositis, Polyarteritis Nodosa, Polymyositis, Psoriatic Arthritis, Relapsing Polychondritis, Rheumatoid Arthritis, Scleroderma, Systemic Lupus Erythematosus, and Vasculitis.
  • Based on End-Use, market is studied across Diagnostic Centers & Laboratories and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness and understanding of collagen vascular diseases
      • 5.1.1.2. Rising incidence of autoimmune diseases globally
      • 5.1.1.3. Improved healthcare infrastructure and increased accessibility to medical services
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with advanced treatments and medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in gene and stem cell therapies
      • 5.1.3.2. Adoption of telemedicine, mobile health applications, and wearables for patient management
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations and approval processes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increasing usage of biopsy kits in collagen vascular diseases
    • 5.2.2. Indication: Increasing utilization for indicating dermatomyositis
    • 5.2.3. End-Use: Expanding usage among diagnostic centers & laboratories to diagnose various health conditions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Collagen Vascular Diseases Market, by Product

  • 6.1. Introduction
  • 6.2. Diagnosis
    • 6.2.1. Biopsy
    • 6.2.2. Blood Test
    • 6.2.3. Echocardiogram
    • 6.2.4. Imaging Tests
    • 6.2.5. Urinalysis
  • 6.3. Treatments
    • 6.3.1. Medications
    • 6.3.2. Physical Therapy

7. Collagen Vascular Diseases Market, by Indication

  • 7.1. Introduction
  • 7.2. Ankylosing Spondylitis
  • 7.3. Dermatomyositis
  • 7.4. Polyarteritis Nodosa
  • 7.5. Polymyositis
  • 7.6. Psoriatic Arthritis
  • 7.7. Relapsing Polychondritis
  • 7.8. Rheumatoid Arthritis
  • 7.9. Scleroderma
  • 7.10. Systemic Lupus Erythematosus
  • 7.11. Vasculitis

8. Collagen Vascular Diseases Market, by End-Use

  • 8.1. Introduction
  • 8.2. Diagnostic Centers & Laboratories
  • 8.3. Hospitals & Clinics

9. Americas Collagen Vascular Diseases Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Collagen Vascular Diseases Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Collagen Vascular Diseases Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
    • 12.3.2. FDA Approves First Tocilizumab Biosimilar For Treatment Of Rheumatoid Arthritis, JIA
    • 12.3.3. American College of Rheumatology Launches New Toolkit Aimed at Measuring Rheumatoid Arthritis Outcomes
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Apollo Health and Lifestyle Limited
  • 4. Augurex Life Sciences Corporation
  • 5. Bayer AG
  • 6. Beckman Coulter, Inc.
  • 7. Bio-Rad Laboratories Inc.
  • 8. Boehringer Ingelheim International GmbH
  • 9. Bristol-Myers Squibb
  • 10. Eli Lilly and Company
  • 11. Exagen Inc.
  • 12. F. Hoffmann-La Roche Ltd
  • 13. Getinge AB
  • 14. Gilead Sciences, Inc.
  • 15. Illumina, Inc.
  • 16. Laboratory Corporation of America Holdings
  • 17. LeMaitre Vascular, Inc.
  • 18. Merck KGaA
  • 19. Novartis AG
  • 20. PerkinElmer, Inc.
  • 21. Pfizer Inc,
  • 22. QIAGEN GmbH
  • 23. Siemens AG
  • 24. Thermo Fisher Scientific, Inc.
  • 25. Trinity Biotech PLC

LIST OF FIGURES

  • FIGURE 1. COLLAGEN VASCULAR DISEASES MARKET RESEARCH PROCESS
  • FIGURE 2. COLLAGEN VASCULAR DISEASES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. COLLAGEN VASCULAR DISEASES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. COLLAGEN VASCULAR DISEASES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COLLAGEN VASCULAR DISEASES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COLLAGEN VASCULAR DISEASES MARKET DYNAMICS
  • TABLE 7. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ECHOCARDIOGRAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DERMATOMYOSITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY POLYARTERITIS NODOSA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY POLYMYOSITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RELAPSING POLYCHONDRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SCLERODERMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 242. COLLAGEN VASCULAR DISEASES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 243. COLLAGEN VASCULAR DISEASES MARKET, FPNV POSITIONING MATRIX, 2023